C5AR1 and Alzheimer disease: Previously, our lab has demonstrated that genetic ablation of C1q [31] or C5aR1 [32, 33], as well as pharmacological inhibition with the C5aR1 inhibitor PMX205 [34, 35], reduces neuroinflammation and/or pathology in AD models and rescues cognitive decline.